Park, Dong Ho <br/><br/>
LOC387715/HTRA1 variants and the response to combined photodynamic therapy with intravitreal bevacizumab for polypoidal choroidal vasculopathy.  [electronic resource] 

 -  Retina (Philadelphia, Pa.)  Feb 2012 
 - 299-307 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1539-2864 
<br/><br/><label>Standard No.: </label>10.1097/IAE.0b013e318225290f  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Angiogenesis Inhibitors--therapeutic use<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Bevacizumab<br/>Choroid Diseases--drug therapy<br/>Combined Modality Therapy<br/>Female<br/>Fluorescein Angiography<br/>Genotype<br/>High-Temperature Requirement A Serine Peptidase 1<br/>Humans<br/>Intravitreal Injections<br/>Male<br/>Middle Aged<br/>Peripheral Vascular Diseases--drug therapy<br/>Pharmacogenetics<br/>Photochemotherapy<br/>Polymorphism, Single Nucleotide<br/>Polyps--drug therapy<br/>Proteins--genetics<br/>Retrospective Studies<br/>Serine Endopeptidases--genetics<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Visual Acuity--physiology